Clinical trials: Head and Neck Cancers- Squamous Cell
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Surgery and Reducing Ionizing Radiation of the Unknown Primary
About 3% of people with head and neck cancer have cancer in their lymph nodes, but doctors are unable to find the primary tumour.
- Trial name
- SUPERIOR (NCT06578871)
- Testing
- Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk, Surgical Intervention, Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck
- Where
- 3 sites in Australia, Canada
- Volunteers
- 90 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Esophageal Squamous Cell Carcinoma
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent radiotherapy for inoperable locally advanced…
- Trial name
- NCT03377400
- Testing
- Durvalumab
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Melanoma, Squamous Cell Carcinoma of Head and Neck
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment.
- Trial name
- NCT05280314
- Testing
- IO102-IO103, Pembrolizumab KEYTRUDA®
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 60 people
- Sponsor
- IO Biotech
Head and Neck Squamous Cell Carcinoma
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies the side effects and how well docetaxel and capecitabine work in treating patients with squamous cell (thin, flat cells) carcinoma of the head and neck that has come back or spread to other places in…
- Trial name
- NCT02524275
- Testing
- Capecitabine, Docetaxel, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Nebraska
Oropharynx Cancer, Squamous Cell Carcinoma of the Oral Cavity
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in patients with resectable oropharyngeal and cavity of the mouth cancer.
- Trial name
- NCT01108042
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
- Where
- 4 sites in Germany
- Volunteers
- 71 people
- Sponsor
- Orlando Guntinas-Lichius, Prof. Dr. med.
Squamous Cell Carcinoma of the Oral Cavity
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21…
- Trial name
- INSPIRE (NCT02609386)
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Where
- 22 sites in United States, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Head and Neck Cancer
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to…
- Trial name
- NCT00004070
- Testing
- IL-12
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA)…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm
- Trial name
- NeoCamre-HN (NCT07400094)
- Testing
- Camrelizumab, Paclitaxel, carboplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
The intratumoral microbiota is a key modulator of the tumor immune microenvironment. This study aims to clinically validate a novel, AI-driven digital pathology biomarker-the Microbial-Sensory Coupling (MSC) index-which measures…
- Trial name
- NCT07745322
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking University Cancer Hospital & Institute
Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer
Oropharyngeal cancer (OPC) is the most common type of head and neck cancer. The current standard treatment for this cancer is radiotherapy (RT) of the tumour and lymph nodes of both sides of the neck, combined with concurrent…
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers, Oropharyngeal Carcinoma, Head and Neck
- Trial name
- SELECT-FR (NCT07241273)
- Testing
- Lymphatic mapping with SPECT-CT, Bilateral neck radiotherapy, Ipsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy
- Where
- 12 sites in France
- Volunteers
- 128 people
- Sponsor
- UNICANCER
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Esophageal Cancer
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544362
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 13 sites in France
- Volunteers
- 33 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cutaneous, Head and Neck Cancer Squamous Cell Carcinoma
Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
The purpose of this study is to compare the effectiveness and side effects of stereotactic radiotherapy (5 sessions) against conventional (standard) radiotherapy (20-30 sessions) for the treatment of skin cancer involving the…
- Trial name
- SPRINT (NCT07337161)
- Testing
- SBRT, Standard Radiation
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- David Palma
Head and Neck Cancer
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
A study evaluating the safety, pharmacokinetics, and biomarker profiles of multiple study drugs as monotherapy in subjects with newly diagnosed, treatment-naïve locally advanced squamous cell carcinoma of the head and neck who…
- Trial name
- NCT03818542
- Testing
- ABBV-181, ABBV-368, ABBV-927
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- AbbVie
Head and Neck Cancer, Radiation
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.
- Conditions
- Head and Neck Cancer, Radiation, PD-1
- Trial name
- NCT04814069
- Testing
- Tislelizumab
- Volunteers
- 38 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Head and Neck Cancer
DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897988
- Testing
- gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Squamous Cell Carcinoma of Head and Neck
Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN
Targeting the PD-L1 pathway with atezolizumab has demonstrated objective responses across a broad range of malignancies including head and neck squamous cell carcinoma (SCCHN).
- Trial name
- PIONEER (NCT04939480)
- Testing
- Atezolizumab
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital, Essen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.